EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Oxurion NV's enterprise value is €11.56 Mil.
Oxurion NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-18.55 Mil. Therefore, Oxurion NV's EV-to-EBITDA for today is -0.62.
The historical rank and industry rank for Oxurion NV's EV-to-EBITDA or its related term are showing as below:
XBRU:OXUR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.96 Med: -0.54 Max: 39.91
Current: -0.62
During the past 13 years, the highest EV-to-EBITDA of Oxurion NV was 39.91. The lowest was -3.96. And the median was -0.54.
XBRU:OXUR's EV-to-EBITDA is ranked worse than 100% of 472
companies
in the Biotechnology industry
Industry Median: 9.005
vs XBRU:OXUR: -0.62
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-23), Oxurion NV's stock price is €0.0001.
Oxurion NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.022. Therefore, Oxurion NV's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Oxurion NV EV-to-EBITDA Historical Data
The historical data trend for Oxurion NV's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Oxurion NV's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxurion NV EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Oxurion NV's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Oxurion NV's EV-to-EBITDA falls into.
Oxurion NV EV-to-EBITDA Calculation
Oxurion NV's EV-to-EBITDA for today is calculated as:
Oxurion NV's current Enterprise Value is €11.56 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oxurion NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-18.55 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oxurion NV (XBRU:OXUR) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Oxurion NV's share price for today is €0.0001.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oxurion NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.022.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Oxurion NV's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Oxurion NV is a clinical stage biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME). The Group's research and development facilities are located in Belgium .The Company is engaged in the development of drugs to treat back-of-the-eye diseases, more specifically, ophthalmologic pharmaceuticals to treat vascular retinal disorders, specifically DME.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XBRU:OXUR has been successfully added to your 